IMV Inc.

is a clinical-stage immuno-oncology company that focuses on developing a portfolio of immune-educating therapies based on its DPX® technology. The company's lead candidate, maveropepimut-S (MVP-S), is designed to treat solid and hematologic cancers by delivering antigenic peptides of survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. IMV's approach aims to generate a specific, robust, and persistent immune response by instructing the immune system. The treatment has shown promising results in multiple cancer indications, with defined clinical benefit and the activation of a targeted and sustained survivin-specific anti-tumor immune response. Currently, MVP-S is undergoing clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL), ovarian, bladder, and breast cancers. IMV Inc. was founded in 2000 and is headquartered in Canada. For further details, please visit www.imv-inc.com.